FIBROBIOLOGICS INC (FBLG) Stock Fundamental Analysis

NASDAQ:FBLG • US31573L1052

0.2829 USD
+0.02 (+7.44%)
At close: Feb 26, 2026
0.2908 USD
+0.01 (+2.79%)
After Hours: 2/26/2026, 8:24:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

Taking everything into account, FBLG scores 0 out of 10 in our fundamental rating. FBLG was compared to 521 industry peers in the Biotechnology industry. FBLG may be in some trouble as it scores bad on both profitability and health. FBLG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year FBLG has reported negative net income.
  • FBLG had a negative operating cash flow in the past year.
FBLG Yearly Net Income VS EBIT VS OCF VS FCFFBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -211.59%, FBLG is doing worse than 88.48% of the companies in the same industry.
  • The Return On Equity of FBLG (-14800.80%) is worse than 82.15% of its industry peers.
Industry RankSector Rank
ROA -211.59%
ROE -14800.8%
ROIC N/A
ROA(3y)-111.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FBLG Yearly ROA, ROE, ROICFBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • FBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBLG Yearly Profit, Operating, Gross MarginsFBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, FBLG has more shares outstanding
  • Compared to 1 year ago, FBLG has a worse debt to assets ratio.
FBLG Yearly Shares OutstandingFBLG Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
FBLG Yearly Total Debt VS Total AssetsFBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -13.84, we must say that FBLG is in the distress zone and has some risk of bankruptcy.
  • FBLG has a worse Altman-Z score (-13.84) than 78.50% of its industry peers.
  • FBLG has a Debt/Equity ratio of 36.58. This is a high value indicating a heavy dependency on external financing.
  • FBLG has a Debt to Equity ratio of 36.58. This is amonst the worse of the industry: FBLG underperforms 81.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 36.58
Debt/FCF N/A
Altman-Z -13.84
ROIC/WACCN/A
WACCN/A
FBLG Yearly LT Debt VS Equity VS FCFFBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

  • A Current Ratio of 0.78 indicates that FBLG may have some problems paying its short term obligations.
  • FBLG has a worse Current ratio (0.78) than 87.72% of its industry peers.
  • A Quick Ratio of 0.78 indicates that FBLG may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.78, FBLG is not doing good in the industry: 87.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.78
FBLG Yearly Current Assets VS Current LiabilitesFBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 45.73% over the past year.
EPS 1Y (TTM)45.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1200%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -13.84% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-37.5%
EPS Next 2Y-0.37%
EPS Next 3Y7.3%
EPS Next 5Y-13.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBLG Yearly Revenue VS EstimatesFBLG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M
FBLG Yearly EPS VS EstimatesFBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • FBLG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year FBLG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBLG Price Earnings VS Forward Price EarningsFBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBLG Per share dataFBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.37%
EPS Next 3Y7.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for FBLG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FIBROBIOLOGICS INC

NASDAQ:FBLG (2/26/2026, 8:24:50 PM)

After market: 0.2908 +0.01 (+2.79%)

0.2829

+0.02 (+7.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31
Earnings (Next)03-30
Inst Owners8.12%
Inst Owner Change-19.4%
Ins Owners9.31%
Ins Owner Change2.26%
Market Cap18.82M
Revenue(TTM)N/A
Net Income(TTM)-18.50M
Analysts82.22
Price Target7.14 (2423.86%)
Short Float %1.56%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.57%
Min EPS beat(2)-18.56%
Max EPS beat(2)-4.58%
EPS beat(4)1
Avg EPS beat(4)-11.49%
Min EPS beat(4)-24.78%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.2%
PT rev (3m)-20%
EPS NQ rev (1m)2.78%
EPS NQ rev (3m)-0.96%
EPS NY rev (1m)1.23%
EPS NY rev (3m)-2.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 150.55
P/tB 150.55
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -211.59%
ROE -14800.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 36.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 160.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.78
Altman-Z -13.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1200%
EPS Next Y-37.5%
EPS Next 2Y-0.37%
EPS Next 3Y7.3%
EPS Next 5Y-13.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-157.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.96%
OCF growth 3YN/A
OCF growth 5YN/A

FIBROBIOLOGICS INC / FBLG FAQ

Can you provide the ChartMill fundamental rating for FIBROBIOLOGICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to FBLG.


What is the valuation status of FIBROBIOLOGICS INC (FBLG) stock?

ChartMill assigns a valuation rating of 0 / 10 to FIBROBIOLOGICS INC (FBLG). This can be considered as Overvalued.


What is the profitability of FBLG stock?

FIBROBIOLOGICS INC (FBLG) has a profitability rating of 0 / 10.


What is the earnings growth outlook for FIBROBIOLOGICS INC?

The Earnings per Share (EPS) of FIBROBIOLOGICS INC (FBLG) is expected to decline by -37.5% in the next year.